The big approvals still on the cards for 2021
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
Arcus nears crunch time for Gilead opt-in
The anti-Tigit MAb domvanalimab will generate key clinical results any day; will they be good enough for Gilead to opt in?
Asco 2021 – Bristol makes more progress in stomach cancer
But the space, a battle between Opdivo and Keytruda, is becoming extremely complex, and Bristol’s win is not unequivocal.
Asco 2021 – financial toxicity in the spotlight
The long overdue advent of US cut-price oncology drugs is a major theme at this year’s Asco, and Junshi’s toripalimab leads the way.
Roche remains big pharma’s biggest R&D spender
As Covid-19 spending pushes the sector’s R&D bill ever higher, Lilly continues to plough the most back in as Sanofi applies the brakes.
